Myelofibrosis: Bone Marrow Scarring, Complications, and Management Options

Myelofibrosis (MF) is a Philadelphia-negative myeloproliferative neoplasm (MPN) characterized by clonal hematopoiesis, cytokine-driven marrow fibrosis, extramedullary hematopoiesis, and constitutional symptoms.

Pathophysiology

  • Driver mutations: JAK2 V617F (60%), CALR (25%), MPL (5–10%), “triple-negative” (10%).
  • Constitutive JAK-STAT signaling → megakaryocyte hyperplasia → TGF-β, PDGF release → fibroblast proliferation → collagen deposition (reticulin → collagen fibrosis).
  • Extramedullary hematopoiesis → splenomegaly, hepatomegaly.

Clinical Manifestations

  • Anemia (normocytic) – transfusion dependence in 30–40%.
  • Splenomegaly (90%) – early satiety, LUQ pain.
  • Constitutional: night sweats, weight loss, fever, pruritus.
  • Thrombosis (arterial/venous) & bleeding (platelet dysfunction).
  • Progression to AML (~10–20% at 10 yrs).

Prognostic Scoring

  • IPSS / DIPSS-plus: Age, Hb, WBC, blasts, symptoms, karyotype, transfusion need, platelets.
  • Risk groups: Low, Int-1, Int-2, High → median survival 1.5–11+ years.

Treatment

Monitoring

CBC q1–3 mo, spleen size (palpation/US), symptom burden (MPN-SAF TSS), mutation allele burden, bone marrow biopsy q1–2 yr.

Blood Disorders - Related Articles

Health Sciences © https://www.222health.com

GoalOptions
Symptom/spleen controlRuxolitinib (JAK1/2 inhibitor) – FDA approved; fedratinib, pacritinib, momelotinib.
AnemiaErythropoiesis-stimulating agents, danazol, immunomodulators (lenalidomide, pomalidomide), luspatercept (emerging).
CurativeAllogeneic HCT – only curative; age/comorbidity/fitness limit eligibility.
SupportiveTransfusions, hydroxyurea (cytoreduction), splenectomy (rare), radiation (symptomatic splenomegaly).